Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03542851Phase 2Unknown

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

Role: lead

NCT02512588Phase 2Completed

A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

Role: lead

NCT03150498Phase 1Completed

A Food Effects Study and Optional Multi Dose Study to Assess PK of BTD-001

Role: lead

NCT03107013Phase 1Completed

A Study to Investigate the Mass Balance of BTD-001

Role: lead

All 4 trials loaded